EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Site‐Specific Modification of Native IgGs with Flexible Drug‐Load

Jöri E Wehrmüller, Julia C Frei iD, Torsten Hechler iD, Michael Kulke, Andreas Pahl, Martin Béhé iD, Roger Schibli iD, Philipp R Spycher iD

ChemBioChem · 2025

DOI: 10.1002/cbic.202400511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Jöri E Wehrmüller und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Radiopharmaceutical Science, ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland. Hauptthemen laut MEDLINE: Immunoconjugates, Trastuzumab, Immunoglobulin G. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FP7 Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homogeneous, site‐specifically conjugated antibodies have shown to result in antibody‐drug conjugates (ADCs) with improved efficacy and tolerability compared to stochastically conjugated ADCs. However, precisely controlling the drug load as well as attaching multiple payload moieties to the antibody remains challenging. Here, we demonstrate the simple and direct modification of native IgG‐antibodies at the residue glutamine 295 (Q295) without the need for any protein engineering with flexible drug‐to‐antibody ratios of one or multiple payloads. The conjugation is enabled through short, positively charged lysine containing peptides and native, commercially available microbial transglutaminase. In proof‐of‐concept studies, HER2‐targeting ADCs based on trastuzumab were generated with drug‐to‐antibody ratios (DARs) of 2 and 4 of the same or different payloads using orthogonal conjugation chemistries. Quantitative biodistribution studies performed with 111 In‐radiolabeled conjugates showed high tumour uptake and low accumulation of radioactivity in non‐targeted tissues. A single dose study of trastuzumab conjugated to the highly potent payload α‐Amanitin demonstrated complete and long‐lasting tumour remission and was well‐tolerated at all dose levels tested.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesTrastuzumabImmunoglobulin GHumansAnimalsMiceErb-b2 Receptor Tyrosine KinasesFemaleTissue DistributionCell Line, Tumor

Stichwörter der Autor:innen

ADCDual-payloadMicrobial transglutaminasePeptideRadio-immunoconjugate

Substanzen

ImmunoconjugatesTrastuzumabImmunoglobulin GErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Center for Radiopharmaceutical Science, ETH-PSI-USZ, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.
  • Heidelberg Pharma Research GmbH, Gregor-Mendel-Straße 22, 68526, Ladenburg, Germany.
  • Department of Chemistry and Applied Biosciences, ETH Zürich, 8093, Zürich, Switzerland.
  • Araris Biotech AG, Riedhofstrasse 11, 8804, Au ZH, Switzerland.

ORCID-Profile: Julia C Frei, Torsten Hechler, Martin Béhé, Roger Schibli, Philipp R Spycher

Förderung

  • FP7 Health

Zitieren

APA

Wehrmüller, J. E., Frei, J. C., Hechler, T., Kulke, M., Pahl, A., Béhé, M., Schibli, R., & Spycher, P. R. (2025). Site‐Specific Modification of Native IgGs with Flexible Drug‐Load. ChemBioChem. https://doi.org/10.1002/cbic.202400511

Vancouver

Wehrmüller JE, Frei JC, Hechler T, Kulke M, Pahl A, Béhé M, et al. Site‐Specific Modification of Native IgGs with Flexible Drug‐Load. ChemBioChem. 2025. doi:10.1002/cbic.202400511

BibTeX
@article{Wehrmller2025,
  author = {Wehrmüller, Jöri E and Frei, Julia C and Hechler, Torsten and Kulke, Michael and Pahl, Andreas and Béhé, Martin and Schibli, Roger and Spycher, Philipp R},
  title = {Site‐Specific Modification of Native IgGs with Flexible Drug‐Load},
  journal = {ChemBioChem},
  year = {2025},
  doi = {10.1002/cbic.202400511}
}
Kostenlos starten →